Lynparza™ (olaparib)

LYNPARZA® est indiqué dans 4 indications thérapeutiques. 

Lynpara (olaparib) est le premier inhibiteur de PARP (Poly-ADP-Ribose-Polymérase), qui permet aux femmes atteintes d'un cancer de l’ovaire récidivant sensible au platine avec une mutation BRCA (BReast CAncer) de prolonger la survie sans progression1-3 

Cancer de l'ovaire

Ressources et supports

Études cliniques

SOLO-1

Vidéos

Dr Luyckx discute les résultats de la SG après 7 ans de suivi

 

Le prof. Baurain discute des résultats de l’analyse primaire (suivi à 3 ans)

 

Publications 

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer 
Moore K. et al. 2018 (initial publication)

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial 
Banerjee S. et al. 2022  (5-year follow-up publication) 

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial  
DiSilvestro P. et al. 2022 (7-year follow-up publication) 

 

SOLO-2

Lien vers la publication


PAOLA-1

Lien vers la publication

MoA et recherche de mutations

Mécanisme d’action

 

Recherche de mutations

Site web: https://www.idbrca.com/ovarian-home.html

Pour vos patientes

Journal pour les patients traités par Lynparza

Événements

Aucun événement pour le moment.

Références

  1. LYNPARZA® 100 mg and 150 mg comprimés pelliculés, Résumé des caractéristiques du produit, version la plus récente
  2. https://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/fr/Public/ProductSearch (accès 25/10/2021)
  3. Weston VJ et al. The PARP inhibitor olaparib induces signicant killing of ATM-decient lymphoid tumour cells in vitro and in vivo. Blood. 2010;116(22):4578–4587.
  4. Weil MK and Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011;35(1):7–50.
  5. Aly A and Ganesan S. BRCA1, PARP, and 53BP1: Conditional synthetic lethality and synthetic viability. J Mol Cell Biol. 2011;3(1):66–74.
  6. Moore K et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
  7. Banerjee S et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO-1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 2021.
  8. Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284.
  9. Capoluongo E et al. Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients. Semin Oncol. 2017;44:187–197.
  10. Vergote I et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127–134.
  11. Pennington et al. Germline and somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas Clin Cancer Res. 2014; 20(3):764–775.
  12. Pal T et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807–2816.
  13. DiSilvestro P et al. Overall survival at 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib in the SOLO1/GOG 3004 trial. Presented at ESMO Congress 2022, Paris, France, September 2022. 

NS ID BE-2975-Revision date 12/2022-WEBLocal code 1697

Retour au sommet